Suppressive thyroxine therapy of differentiated thyroid cancer in daily practice of a large cancer centre

Zbigniew Puch; Józef Roskosz; Beata Jurecka-Lubieniecka; Dorota Kula

Vol 57, Supp. A (2006)

Original paper

Submitted: 2013-02-15

Published online: 2006-09-25

View PDF (Polish)

Download PDF file

Get Citation

Suppressive thyroxine therapy of differentiated thyroid cancer in daily practice of a large cancer centre

Zbigniew Puch, Józef Roskosz, Beata Jurecka-Lubieniecka, Dorota Kula

Vol 57, Supp. A (2006)

Original Paper

Submitted: 2013-02-15

Published online: 2006-09-25

Abstract

Introduction: The study summarizes the results of an audit evaluating the realization of the suppressive TSH therapy in patients with differentiated thyroid cancer.
Material and methods: The evaluation was performed in 500 consecutive patients.
Results: In patients in whom remission was diagnosed < 5 years ago, in 70% subcomplete suppression was stated (TSH 0.1–0.3 mU/L) and complete suppression (TSH < 0.1 mU/L) was observed in 20%. Unexpectedly in patients in whom remission lasted > 5 years, complete suppression was observed in 60%. However, this last group was less numerous, thus, the majority of no evidence of disease patients exhibited subcomplete TSH suppression, while only 40% of patients with active disease had this goal realized.
Conclusions: 1. Iatrogenous hypothyroidism was well controlled in nearly all differentiated thyroid cancer patients.
2. The goal of L-thyroxine treatment, defined as TSH serum level < 0.4 mU/L was achieved in 90% of them without a significant risk of iatrogenous thyrotoxicosis.
3. Some overdosage of L-thyroxine was observed, especially in patients in whom remission lasted > 5 years. It this group of patients there is no reason to induce full suppression of TSH by L-thyroxine treatment.